New drug trial aims to keep advanced lung cancer in check
NCT ID NCT07204548
Summary
This study tests whether a drug called Ivonescimab can help control advanced lung cancer that cannot be surgically removed. After completing standard chemotherapy and radiation, 63 patients will receive Ivonescimab for one year to see if it delays cancer progression. The main goal is to measure how many patients remain progression-free after 12 months while monitoring safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER (STAGE III) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Li-Kun Chen
Guangzhou, Guangzhou, 510006, China
Conditions
Explore the condition pages connected to this study.